Quartz48d agoneutral
Biogen acquires RayThera in deal worth up to $1 billionThe deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
The deal adds multiple small-molecule anti-inflammatory drug candidates to Biogen's pipeline, with the lead asset set to begin human trials this summer
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.